Primary pancreatic lymphoma: A case report and review of literature.

IF 2.6 Q3 ONCOLOGY World journal of clinical oncology Pub Date : 2024-11-24 DOI:10.5306/wjco.v15.i11.1444

Marko M Stojanovic, Vesna Brzacki, Goran Marjanovic, Milica Nestorovic, Jelena Zivadinovic, Miljan Krstic, Marko Gmijovic, Ilija Golubovic, Svetlana Jovanovic, Miroslav P Stojanovic, Katarina Terzic

{"title":"Primary pancreatic lymphoma: A case report and review of literature.","authors":"Marko M Stojanovic, Vesna Brzacki, Goran Marjanovic, Milica Nestorovic, Jelena Zivadinovic, Miljan Krstic, Marko Gmijovic, Ilija Golubovic, Svetlana Jovanovic, Miroslav P Stojanovic, Katarina Terzic","doi":"10.5306/wjco.v15.i11.1444","DOIUrl":null,"url":null,"abstract":"Background: Primary pancreatic lymphoma (PPL) is a rare tumor that mimics pancreatic adenocarcinoma, leading to diagnostic and therapeutic challenges. PPL accounts for 0.2% of all pancreatic tumors and is typically treated with chemotherapy. However, the long-term survival rates for PPL with chemotherapy and radiotherapy alone are unsatisfactory. Due to the improvements in pancreatic surgery, there is a need to reevaluate the treatment strategies for PPL.Case summary: A 62-year-old male presented to our clinic. A biopsy was unsuccessful, and the imaging was suggestive of pancreatic adenocarcinoma. Therefore, subtotal splenopancreatectomy was performed and histopathology was performed. He was then diagnosed with primary pancreatic diffuse large B-cell lymphoma. He received adjuvant chemotherapy and radiotherapy. Currently, the patient is alive with no evidence of disease 36 months after surgery.Conclusion: The potential role of surgery in the treatment of PPL should be emphasized and added in the management protocol of early stage lymphoma.","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"15 11","pages":"1444-1453"},"PeriodicalIF":2.6000,"publicationDate":"2024-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11514422/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World journal of clinical oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5306/wjco.v15.i11.1444","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Primary pancreatic lymphoma (PPL) is a rare tumor that mimics pancreatic adenocarcinoma, leading to diagnostic and therapeutic challenges. PPL accounts for 0.2% of all pancreatic tumors and is typically treated with chemotherapy. However, the long-term survival rates for PPL with chemotherapy and radiotherapy alone are unsatisfactory. Due to the improvements in pancreatic surgery, there is a need to reevaluate the treatment strategies for PPL.

Case summary: A 62-year-old male presented to our clinic. A biopsy was unsuccessful, and the imaging was suggestive of pancreatic adenocarcinoma. Therefore, subtotal splenopancreatectomy was performed and histopathology was performed. He was then diagnosed with primary pancreatic diffuse large B-cell lymphoma. He received adjuvant chemotherapy and radiotherapy. Currently, the patient is alive with no evidence of disease 36 months after surgery.

Conclusion: The potential role of surgery in the treatment of PPL should be emphasized and added in the management protocol of early stage lymphoma.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

原发性胰腺淋巴瘤：病例报告和文献综述

背景：原发性胰腺淋巴瘤（PPL）是一种模拟胰腺腺癌的罕见肿瘤，给诊断和治疗带来了挑战。原发性胰腺淋巴瘤占所有胰腺肿瘤的 0.2%，通常采用化疗治疗。然而，仅靠化疗和放疗治疗 PPL 的长期生存率并不令人满意。由于胰腺手术的改进，有必要重新评估 PPL 的治疗策略。活组织检查未获成功，影像学检查提示为胰腺腺癌。因此，我们对他进行了脾胰次全切除术，并进行了组织病理学检查。随后，他被诊断为原发性胰腺弥漫大 B 细胞淋巴瘤。他接受了辅助化疗和放疗。目前，患者在术后 36 个月仍健在，没有任何疾病迹象：结论：手术在治疗胰腺弥漫性大 B 细胞淋巴瘤中的潜在作用应得到重视，并应纳入早期淋巴瘤的治疗方案中。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

World journal of clinical oncology ONCOLOGY-

自引率

0.00%

发文量

585

期刊介绍： The WJCO is a high-quality, peer reviewed, open-access journal. The primary task of WJCO is to rapidly publish high-quality original articles, reviews, editorials, and case reports in the field of oncology. In order to promote productive academic communication, the peer review process for the WJCO is transparent; to this end, all published manuscripts are accompanied by the anonymized reviewers’ comments as well as the authors’ responses. The primary aims of the WJCO are to improve diagnostic, therapeutic and preventive modalities and the skills of clinicians and to guide clinical practice in oncology. Scope: Art of Oncology, Biology of Neoplasia, Breast Cancer, Cancer Prevention and Control, Cancer-Related Complications, Diagnosis in Oncology, Gastrointestinal Cancer, Genetic Testing For Cancer, Gynecologic Cancer, Head and Neck Cancer, Hematologic Malignancy, Lung Cancer, Melanoma, Molecular Oncology, Neurooncology, Palliative and Supportive Care, Pediatric Oncology, Surgical Oncology, Translational Oncology, and Urologic Oncology.